title: Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes.
abstract: Obesity increases the risk of diabetes up to 90-fold and worsens hyperglycemia, hyperinsulinemia, insulin resistance, dyslipidemia, and nonalcoholic fatty liver disease. For patients with type 2 diabetes, weight loss can trigger improvements in all these conditions and decrease the need for glucose-lowering agents. The incretin mimetic exenatide shares many glucoregulatory properties with native glucagon-like peptide-1, including enhancement of glucose-dependent insulin secretion, glucose-dependent suppression of inappropriately high glucagon secretion, slowing of gastric emptying, and reduction of food intake in patients with type 2 diabetes. Exenatide treatment was associated with progressive weight loss in the majority of patients in clinical trials. In addition, patients with elevated markers of liver injury at baseline showed improvements. Therefore, exenatide represents a unique option for adjunctive therapy for patients with type 2 diabetes not achieving adequate glycemic control on oral antidiabetic agents, especially in patients for whom weight gain would be an additional contraindication.
authors.affiliation: Amylin Pharmaceuticals, Inc., San Diego, California 92121, USA. lnielsen@amylin.com
authors.forename: Loretta L
authors.initials: LL
authors.lastname: Nielsen
authors.forename: Ted
authors.initials: T
authors.lastname: Okerson
authors.forename: John
authors.initials: J
authors.lastname: Holcombe
authors.forename: Byron
authors.initials: B
authors.lastname: Hoogwerf